Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
arcotatug tavatecan (IBI-343)
i
Other names:
IBI-343, IBI343
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Innovent Biologics
Drug class:
Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
Related drugs:
‹
fam-trastuzumab deruxtecan-nxki (90)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
datopotamab deruxtecan (11)
DM001 (6)
DS-7300 (5)
AZD8205 (5)
AMB302 (4)
DB-1310 (4)
DM002 (4)
BNT323 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
sacituzumab tirumotecan (3)
nanoliposomal irinotecan (3)
PLX038 (3)
ABBV-400 (3)
CUSP06 (2)
DAN-222 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
BAT8008 (1)
BL-M02D1 (1)
BNT324 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
HMBD-501 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
OQY-3258 (1)
PF-08046044 (1)
rinatabart sesutecan (1)
SGN-CD30C (1)
SHR-A2102 (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
BL-B01D1 (1)
AZD5335 (1)
ABBV-706 (0)
ARC-401 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT326 (0)
CEB-01 (0)
CPO301 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GEN1160 (0)
GSK5733584 (0)
GSK5764227 (0)
HA-irinotecan (0)
HLX43 (0)
IBI-130 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
LMP744 (0)
LY4170156 (0)
lentinan (0)
TLC388 (0)
MHB036C (0)
MHB088C (0)
NK012 (0)
etirinotecan pegol (0)
SHR-A1912 (0)
SKB315 (0)
TQB2102 (0)
TQB2103 (0)
VIP236 (0)
YL201 (0)
CBX-12 (0)
JSKN003 (0)
EP0057 (0)
SHR-A1904 (0)
LMP400 (0)
HR070803 (0)
irinotecan liposomal (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
SSS22 (0)
M9140 (0)
DS-6000 (0)
SHR-A2009 (0)
simmitecan (0)
SHR-A1921 (0)
topotecan episcleral (0)
EO-3021 (5)
SOT102 (5)
AZD0901 (4)
LM-302 (3)
ATG-022 (1)
RC118 (0)
fam-trastuzumab deruxtecan-nxki (90)
irinotecan (48)
U3-1402 (28)
sacituzumab govitecan-hziy (17)
topotecan (16)
SHR-A1811 (15)
datopotamab deruxtecan (11)
DM001 (6)
DS-7300 (5)
AZD8205 (5)
AMB302 (4)
DB-1310 (4)
DM002 (4)
BNT323 (4)
BL-M07D1 (3)
DS-6157 (3)
HRA00129-C004 (3)
sacituzumab tirumotecan (3)
nanoliposomal irinotecan (3)
PLX038 (3)
ABBV-400 (3)
CUSP06 (2)
DAN-222 (2)
DM005 (2)
PRO1102 (2)
SSH20 (2)
IMMU-130 (2)
AZD9592 (2)
AMT-562 (1)
BAT8008 (1)
BL-M02D1 (1)
BNT324 (1)
camptothecin nanosomal (1)
DAN-311 (1)
ELU001 (1)
HMBD-501 (1)
IMMU-140 (1)
IT-141 (1)
OBI-992 (1)
OQY-3258 (1)
PF-08046044 (1)
rinatabart sesutecan (1)
SGN-CD30C (1)
SHR-A2102 (1)
STRO-003 (1)
ZW191 (1)
ZW220 (1)
ZW251 (1)
BL-B01D1 (1)
AZD5335 (1)
ABBV-706 (0)
ARC-401 (0)
BAT8007 (0)
BAT8010 (0)
BL-M11D1 (0)
BNT326 (0)
CEB-01 (0)
CPO301 (0)
belotecan (0)
DS-3939 (0)
FZ-AD004 (0)
GEN1160 (0)
GSK5733584 (0)
GSK5764227 (0)
HA-irinotecan (0)
HLX43 (0)
IBI-130 (0)
IBI-354 (0)
ICAM‑1 ADC (0)
LMP744 (0)
LY4170156 (0)
lentinan (0)
TLC388 (0)
MHB036C (0)
MHB088C (0)
NK012 (0)
etirinotecan pegol (0)
SHR-A1912 (0)
SKB315 (0)
TQB2102 (0)
TQB2103 (0)
VIP236 (0)
YL201 (0)
CBX-12 (0)
JSKN003 (0)
EP0057 (0)
SHR-A1904 (0)
LMP400 (0)
HR070803 (0)
irinotecan liposomal (0)
LY01616 (0)
FF-10850 (0)
PEN-866 (0)
SSS22 (0)
M9140 (0)
DS-6000 (0)
SHR-A2009 (0)
simmitecan (0)
SHR-A1921 (0)
topotecan episcleral (0)
EO-3021 (5)
SOT102 (5)
AZD0901 (4)
LM-302 (3)
ATG-022 (1)
RC118 (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer (NCT06770439)
Phase 2
Zhejiang University
Zhejiang University
Not yet recruiting
Phase 2
Zhejiang University
Not yet recruiting
Last update posted :
01/13/2025
Initiation :
01/01/2025
Primary completion :
01/01/2027
Completion :
01/01/2028
CLDN18
|
gemcitabine • albumin-bound paclitaxel • arcotatug tavatecan (IBI-343)
Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06321913)
Phase 2
Harbin Medical University
Harbin Medical University
Not yet recruiting
Phase 2
Harbin Medical University
Not yet recruiting
Last update posted :
03/20/2024
Initiation :
03/15/2024
Primary completion :
12/31/2025
Completion :
12/31/2025
CLDN18
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • arcotatug tavatecan (IBI-343)
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (NCT05458219)
Phase 1
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
Recruiting
Phase 1
Innovent Biologics (Suzhou) Co. Ltd.
Recruiting
Last update posted :
11/11/2022
Initiation :
10/26/2022
Primary completion :
05/31/2024
Completion :
10/31/2024
CLDN18
|
arcotatug tavatecan (IBI-343)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login